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Clinical and pathophysiologic spectrum of acquired distal renal tubular
acidosis. Urinary acidification was studied in nine patients with hyper-
chioremic metabolic acidosis. The aim of this study was to investigate
the mechanism(s) of impaired distal acidification by the systematic
administration of sodium sulfate and neutral phosphate. No impairment
of proximal acidification was apparent because all patients had a
fractional bicarbonate excretion below 5% at plasma bicarbonate con-
centrations above 22 mEq/liter. All patients except two were unable to
lower urine pH below 5.5 despite systemic metabolic acidosis. The two
patients who lowered urine pH normally were hyperkalemic and had
selective aldosterone deficiency. Six patients failed to lower the urine
pH below 5.5 with sodium sulfate (6.04 0.16) and were unable to
achieve a normal urine minus blood (U-B) Pco2 gradient with neutral
phosphate (2.8 3.5 mm Hg). Control subjects, the two patients with
selective aldosterone deficiency, and the remaining patient lowered the
urine pH below 5.5 and increased the U-B Pco2 gradient above 25 mm
Hg in response to sodium sulfate and neutral phosphate infusion,
respectively. The abnormal response to these agents exhibited by six
patients strongly suggests that the mechanism of impaired distal acidifi-
cation was that of secretory failure of the proton pump. The normal
response of the remaining three patients indicates that the proton pump
was able to secrete hydrogen ions normally under maximal stimulation.
This pattern is totally predictable in patients with isolated selective
aldosterone deficiency who are also capable of lowering the urine pH
normally in the presence of systemic metabolic acidosis. The distinctive
acidification pattern of the remaining patient who was also hyperkale-
mic can be explained on the basis of a voltage-dependent type of distal
renal tubular acidosis. This type may be disclosed by the findings of
impairment of both hydrogen ion and potassium secretion.
Aspects clinique et physiopathologique de l'acidose tubulaire distale
acquise. L'acidification urinaire a été étudiée chez neuf malades ayant
une acidose metabolique hyperchlorémique. Le but de cc travail était
d'étudier le mécanisme de l'altération de lacidification distale par
l'administration de sulfate de sodium et de phosphate neutre. II nest
pas apparu d'altération de l'acidication proximale puisque tous les
malades avaient une excretion fractionnelle de bicarbonate inférieure a
a des concentrations de bicarbonate plasmatique supCrieures a 22
mEq/litre. Tous les malades saufdeux étaient incapables d'abaisser leur
pH urinaire au dessous de 5,5 malgré l'acidose metabolique. Les deux
malades qui abaissaient le pH de l'urine a des valeurs normales étaient
hyperkaliémiques et avaient un deficit sélectif d'aldostérone. Six ma-
lades n'ont pu abaisser leur pH urinaire en dessous de 5,5 avec Ic sulfate
de sodium (6,04 0,16) et ant etC incapables de rCaliser un gradient de
Pco2 normal urine-sang sous phosphate neutre (2,8 3,5 mm Hg). Les
sujets contrôles, les deux malades ayant un deficit d'aldostérone et Ic
dernier malade ont abaissé le pH de l'urine au dessous de 5,5 et
augmentC le gradient de Pco2 a plus de 25 mm Hg en réponse aux
administrations de sulfate de sodium et de phosphate neutre, respec-
tivement. La response anormale des six malades suggCre fortement que
le mécanisme de l'altération de l'acidification distale est un défaut de
fonctionnement de Ia pompe a protons. La réponse normale des trois
derniers malades indique que Ia pompe était capable de secréter des
ions hydrogene dans des conditions de stimulation maximales. Cette
modalité est previsible chez les malades qui ont un deficit sélectif et
isolC d'aldostérone et qui sont aussi capables d'abaisser Ic pH de leur
urine en presence d'une acidose metabolique systémique. La modalité
d'acidification particuliCre du dernier malade qui Ctait en méme temps
hyperkaliemique peut Ctre expliquee par un mécanisme dépendant de Ia
difference de potentiel. Cette situation peut étre reconnue par Ia
constatation d'un désordre portant a La fois sur Ia secretion de ions
hydrogene et celle de potassium.
It is useful to divide patients with renal tubular acidosis
(RTA) into two main categories based on two major patterns of
bicarbonate excretion [1—101. Patients who excrete more than
15% of the filtered bicarbonate at normal plasma bicarbonate
concentrations are said to have proximal RTA [6]. Patients with
distal renal tubular acidosis (DRTA) excrete less than 5%of the
filtered bicarbonate at normal plasma bicarbonate concentra-
tions [61. Patients with proximal RTA may be able to lower
urine pH below 5.5 when plasma bicarbonate falls below their
tubular threshold for bicarbonate reabsorption [5,61. Patients
with "pure" DRTA are unable to lower urine pH normally in
the presence of systemic metabolic acidosis regardless of its
severity [1—121. Overlaps between proximal and distal RTA
occur as shown by the fact that some patients with significant
bicarbonate wastage are not able to lower urine pH even when
they are profoundly acidotic (type III RTA) [1, 61. In both
proximal and distal RTA, impaired acid excretion results in
hyperchioremic metabolic acidosis and often is complicated by
potassium depletion [1—10].
It has been widely accepted that the mechanism responsible
for DRTA is the inability of the distal nephron to develop and
maintain a steep hydrogen ion gradient between the extracellu-
lar fluid and the tubular urine [1—4, 6, 9, 12]. Hence, DRTA is
also referred to as gradient limitation RTA (synonymous terms
include type 1 RTA and classical RTA). This notion was
challenged by Halperin et al, who suggested that DRTA results
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Table 1. Clinical and biochemical features in patients with hyperchioremic metabolic acidosis
Patient
no.
Renal disease!
associated conditions Age/sex Race
Plasma
creatinine
mg/dl
SNa SK s SHCO Anion
gap
mEq/hiter
Blood
pH
Blood
Pco2
mm Hg
Urine
pH
FEHCO3b
%mEqihiter
1* Nephrocalcinosis/Htn 64 F C 1.5 139 3.4 110 16 16.4 7.27 36 6.80 0.60
2 Liver cirrhosis, unknown 54 M C 2.0 135 3.4 110 17 11.5 7.29 35 5.75 0.88
nephropathy pancreatic
insufficiency,
hypoproteinemia
3 Renal transplant/Htn 41 F B 1.7 140 4.7 113 15 16.0 7.29 34 5.97 0.36
4 Renal transplant/Htn 27 F S 2.0 140 4.2 110 16 18.2 7.33 32 6.44 0.85
5 Neurogenic bladder/DM 52 F B 4.5 141 4.3 116 15 14.0 7.31 32 7.56 4.20
6* SC Hemoglobinopathy/Htn 50 M B 1.9 140 5.6 116 11 18.6 7.26 24 6.05 0.70
7 Toxic interstitial nephritis 59 M B 3.9 136 6.0 108 15 19.0 7.28 32 6.24 0.28
(?)/Htn
8 Hyporeninemic 53 M B 1.7 141 5.7 111 21 15.0 7.28 46 5.04 0.02
hypoaldosteronism/DM
9 Hyporeninemic 70 M C 2.2 138 5.8 108 18 18.0 7.32 36 4.79 0.02
hypoaldosteronism/DM
The above values were obtained during spontaneous acidosis or ammonium-chioride-induced acidosis (indicated by asterisk) in two patients.
Htn is hypertension; DM, diabetes mellitus; B, Black; C, Caucasian; S, Spanish.
b The fractional excretion of bicarbonate (FEHc03) was obtained on a separate occasion when plasma bicarbonate was above 22 mEq/liter except
in patients 8 and 9.
from an impairment of hydrogen ion secretion rather than from
an inability to maintain a steep pH gradient between blood and
urine [13]. Experimental studies using membranes analogous to
the human collecting duct have provided conclusive evidence
that mechanisms other than a secretory failure can also result in
deranged distal acidification [14—16].
Based on animal models of defective distal acidification, our
idea was that the mechanism of DRTA could be characterized
by assessing the response to sodium sulfate and neutral phos-
phate administration [17—22]. A normal response to either
sodium sulfate or neutral phosphate would indicate that the
distal mechanism for hydrogen ion secretion is sufficiently
intact to respond to maneuvers which stimulate acidification.
Failure to lower the urine pH with sodium sulfate and the
inability to elevate the U-B Pco2 gradient with phosphate would
strongly support the concept that DRTA is due to an isolated
secretory defect in the distal nephron.
There are occasional observations in the literature on the use
of these agents in patients with DRTA [23—31]. Both tests,
however, were never applied in a combined and systematic
fashion. By examining the response to sodium sulfate and
neutral phosphate administration in normal subjects and in
patients with hyperchloremic metabolic acidosis, this study
seeks to characterize the pathophysiologic mechanism(s) re-
sponsible for the generation of distal acidification defects in
humans.
Methods
Nine patients with hyperchloremic metabolic acidosis and
three normal subjects were studied. Each patient had mild or
moderate renal insufficiency with persistent hyperchioremic
metabolic acidosis (Table 1). The clinical characteristics of the
renal disease of these patients satisfied the criteria of interstitial
nephritis [32]. The main clinical diagnosis and other associated
conditions are listed in Table 1. The diagnosis of DRTA was
made by the inability to lower the urine pH below 5.5 in spite of
spontaneous systemic acidosis (blood pH below 7.33, plasma
bicarbonate of 15 mEq/liter or below) in seven patients. Two of
them (patients 1 and 6) were further studied after an oral acid
loading test with ammonium chloride (0.1 g/kg of body wt daily
for 3 days). The remaining two patients (8 and 9) lowered the
urine pH below 5.5 with spontaneous metabolic acidosis as they
had isolated hypoaldosteronism (see below). Fractional bicar-
bonate excretion (clearance bicarbonate divided by clearance
creatinine x 100) was measured in all patients to rule out a
proximal leak in bicarbonate reabsorption. When proximal
RTA is present, the fractional bicarbonate excretion usually
exceeds 15% at normal plasma bicarbonate concentrations [6].
All our patients had a value of fractional bicarbonate excretion
below 5%, which, thus, excludes a significant leakage of
bicarbonate from the proximal nephron. In addition, a bicar-
bonate titration study was performed in two patients (6 and 7).
Both patients exhibited normal bicarbonate reabsorption at
normal or high levels of plasma bicarbonate concentration.
The studies were carried out on out-patient basis at the
University of Illinois Hospital with the approval of its Institu-
tional Review Committee; written consent from each patient
was obtained. The patients were allowed to continue their
normal diets at the time of all the studies. If they had been
taking any diuretics, alkalinizing solutions, or other medica-
tions that could affect urinary acidification, these drugs were
discontinued for 1 week prior to the studies. All studies were
performed in the morning. After obtaining blood and urine
samples for baseline determination of electrolytes, we instruct-
ed the patients to empty their bladders completely; timed urine
collections were then begun. The urine was collected under
mineral oil for measurement of urine pH and carbon dioxide
tension. Because inability to achieve a minimum urine pH in the
supine position has been previously observed [33], all patients
were instructed to urinate in the upright position. Tap ice-water
was given ad lib to guarantee an adequate urinary output.
Venous blood was obtained from a heparinized indwelling
catheter at the midpoint of each collection. The urine collec-
tions were of approximately 30 to 60 mm duration. Glomerular
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filtration rate (GFR) was measured either by the clearance of
endogenous creatinine or by the administration of I'25-iothala-
mate in a dose of 10 Ci with 0.1 ml of epinephrine s.c. 1 hour
before starting the clearance collections, Two basic protocols
were followed:
(1) Sodium sulfate infusion. In this protocol, the patients and
controls were given 1 mg of fludrocortisone orally the night
before the study to guarantee that sufficient levels of mm-
eralocorticoid were present, thus ensuring a state of sodium
avidity in all cases. Two control clearance collections of
approximately 30 to 60 mm each were obtained and followed by
the i.v. administration of a 500-mI solution of 4% sodium
sulfate, which was infused over a period of 45 to 60 mm. Four
clearance collections were completed at 60, 120, 180, and 240
mm after the beginning of the sodium sulfate infusion.
(2) Neutral phosphate infusion. This study was performed on
a separate day. After completion of two control clearance
collections of 30 to 60 mm each, a solution of 0.2 M neutral
phosphate was infused at a rate of 1 to 1.5 mI/mm for 120 to 180
mm. The study was terminated if the urinary Pco2 failed to rise
3 hours after the beginning of the infusion in spite of a urinary
phosphate concentration above 15 mM. In the subjects in which
the urinary pH was not close to the pK of the phosphate system
(6.8), a solution of 0.9 M sodium bicarbonate was infused prior
to the infusion of phosphate to achieve a urinary pH as close as
possible to 6.8.
Plasma and urine electrolytes were measured as previously
described [34]. Titratable acidity was measured as the amount
of 0.1 N sodium hydroxide required to titrate I ml of urine
sample from the urine pH up to the blood pH. Ammonium was
measured by the formalin titrimetric method of Cunnarro and
Weiner [35].
Plasma cortisol (at 9 A.M.) and plasma aldosterone were
determined using a standard radioimmunoassay kit (Diagnostic
Products Corp., Los Angeles). Plasma renin activity was mea-
sured by radioimmunossay (E. R. Squibb and Sons, Inc.,
Princeton). Acute volume contraction was induced by the
administration of three oral doses of 40 mg of furosemide the
day before the determinations (at 6 P.M., 12 midnight, and 6
A.M.). Blood samples were obtained at 9 A.M. The normal
values obtained in our laboratory with this protocol are 3.6
1.2 ng/ml/hr for plasma renin activity and 26.5 4.76 ng/dl for
plasma aldosterone. To account for the effect of plasma potassi-
um on plasma aldosterone levels, we used the ratio of plasma
aldosterone/plasma potassium. Hyperkalemic patients with iso-
lated hypoaldosteronism exhibit a ratio of plasma aldosterone!
plasma potassium below 3 [36]. Fractional excretion of sodium
and potassium were calculated by the formulas: clearance of
sodium divided by GFR x 100 and clearance of potassium
divided by GFR x 100, respectively. Statistical analyses were
done using the Student's t test for paired or unpaired data when
appropriate. Data are presented as the means SEM. No
adverse side effects occurred during these studies.
Results
General data. As shown in Table 1, the population of patients
included in this study was heterogeneous. Some suffered from
clinical disorders such as nephrocalcinosis, sickle cell (SC)
disease, bladder dysfunction, or had undergone renal transplan-
tation. One patient (patient 2) had liver cirrhosis, pancreatic
Table 2. Renin-aldosterone and aldosterone-potassium relationship
after acute volume contractiona
Patient
no.
SK
mEq/
liter
PRA
ng/
mi/hr
Plasma
aldosterone
ng/di PAIdO/PK
Minimal urine
pH during
acidosis
1 3.4 2.8 28.0 8.2 6.8
2 3.4 0.17 1.0 0.3 5.75
3 4.7 13.9 39.9 10.2 5.97
4 3.7 2.9 7.4 2.1 6.44
5 4.3 0.17 9.1 2.1 7.30
6 5.6 4.4 25.7 4.6 6.05
7 5.8 0.36 8.3 1.4 6.24
8 5.7 0.10 3.9 0.7 5.04
9 5.6 0.14 2.7 0.5 4.79
a All the above values were obtained from blood collected after acute
volume contraction induced by furosemide. The minimal urine pH
observed during acidosis is included for comparison purposes.
insufficiency, hypoalbuminemia, and hypergiobulinemia. Pa-
tient 7 presented with advanced renal failure and a long-
standing history of hypertension; he had been exposed to
several heavy metals, mainly chromium and lead. Heavy metal
nephropathy may result in proximal RTA [6], but this patient
exhibited a normal maximal bicarbonate reabsorption pattern
during a bicarbonate titration study. Because hypertensive
nephrosclerosis is not associated with DRTA, we tentatively
ascribed the etiology of his distal acidification defect to toxic
interstitial nephritis. Patients 8 and 9 were diabetic and'fulfilled
the criteria for the diagnosis of the syndrome of hyporeninemic
hypoaldosteronism (see below).
Table 1 also summarizes the biochemical features of the
patients. Plasma creatinine was elevated in all of the patients
ranging from 1.5 to 4.5 mg/dl. All of them had spontaneous
hyperchloremic metabolic acidosis (mean blood pH, 7.29
0.01; mean blood Pco2, 34 1.9 mm Hg; mean plasma
bicarbonate, 14.9 1.5 mEq/liter; mean plasma chloride, Ill
1.0 mEq/liter; mean anion gap, 16.3 0.8 mEq/liter) while
untreated or after 1 week of discontinuation of all medications.
Despite the presence of chronic metabolic acidosis, seven
patients failed to lower the urine pH below 5.5. Two patients (8
and 9) lowered the urine pH normally with systemic acidosis.
Fractional bicarbonate excretion measured at plasma bicarbon-
ate concentrations above 22 mEq/liter was less than 5% in all of
the patients.
Plasma potassium was normal in three patients (3, 4, and 5),
intermittently low in two (I and 2) and elevated in the remaining
four (7, 6, 8, and 9). The hypokalemia of patient 2 was ascribed
to diarrhea from pancreative insufficiency. Potassium excretion
was not higher in the hyperkalemic patients (53.5 17 Eq/
mm) than that of controls (69 15 j.Eq/min) or the remaining
five patients (46.8 4.1 Eq/min). Potassium excretion cor-
rected for GFR was lower in the hyperkalemic patients (126
27 Eq/dl of GFR) than that of the remaining patients (170 67
Eq/dl of GFR); this difference was not statistically significant.
Plasma cortisol levels were normal in all cases ranging from
12.5 to 23 p.g/dl.
Following acute volume contraction induced by furosemide
(Table 2), four patients (1, 3, 4, and 6) exhibited normal values
of plasma renin activity, plasma aldosterone, and plasma aldos-
terone/plasma potassium ratio. One patient (5) had subnormal
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Table 3. Effect of sodium sulfate on urinary acidificationa
Patient
no.
GFR, mi/mm
C SO4
Bloo
C
d pH
SO4
Urin
C
e pH
SO4
TA Ex
i.Eq/dl GFR
C SO4
NH4 Ex
i.Eq/dl GFR
C SO4
Net acid Ex
p.Eq/dl GFR
C SO4
FE
C
Na
SO4
F
C
EK
%
SO4
1 68 64 7.36 7.36 6.80 6.77 3.4 4.7 5.8 16 —0.4 —5.9 0.9 5.1 18 194
2 39 54 7.29 7.28 5.75 5.58 46 40 55 74 99 120 1.8 3.5 20 30
3 43 48 7.31 7.35 5.93 5.82 39 32 37 27 67 56 3.7 5.5 32 44
4 38 31 7.40 7.43 6.69 6.16 13 18 62 72 56 81 3.1 4.1 40 85
5 11 11 7.32 7.24 7.69 6,00 0 98 189 100 54 182 4.2 11 99 135
7 14 17 7.33 7.33 5.96 5.94 56 62 23 32 73 85 2.5 8.5 35 78
Mean 35.5 37.5 7.33 7.33 6.47 6.04 26 43 62 53 58 86 2.7 6.3 41 94
±SEM ±8.6 ±8.6 ±0.01 ±0.02 ±0.29 ±0.16 ±10 ±14 ±26 ±13 ±13 ±26 ±0.5 ±1.2 ±12 ±25
6 41 53 7.32 7.34 6.26 5.02 67 112 71 186 134 299 1.5 9.2 15 67
8 97 99 7.33 7.34 5.04 5.03 32 21 14 8.8 46 30 1.0 3.6 20 30
9 45 45 7.27 7.33 4.97 4.84 57 63 41 33 97 96 2.5 4.3 22 35
Mean 61 66 7.31 7.33 5.42 4.96 52 65 42 102 92 141 1.6 5.7 19 44
±SEM ±18 ±17 ±0.01 ±0.002 ±0.41 ±0.05 ±10 ±26
Controls
±16 ±44 ±25 ±81 ±0.4 ±1.7 ±15 ±11
10 147 115 7.42 7.19 6.64 4.69 3.3 20 4.7 17 4.7 36 0.6 2.8 15 36
11 111 126 7.37 7.36 6.30 5.20 5.4 14 11 15 15 30 0.5 3.3 10 47
12 146 131 7.43 7.41 5.27 4.35 31 50 17 23 47 74 0.04 2.7 13 41
Mean 135 124 7.40 7.32 6.07 4.74 13 28 10.7 18.5 22 47 0.4 2.9 12.5 41
±SEM ±11 ±4.7 ±0.01 ±0.06 ±0.4 ±0.24 ±9 ±11 ±3.4 ±2.4 ±13 ±8 ±0.2 ±0.1 ±1.6 ±2.9
a TA Ex is titratable acid excretion; NH4, ammonium; FENa and FEK, fractional sodium and potassium excretion; C, control; SO4,
sulfate infusion.
sodium
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Fig. 1. Urine pH values achieved by controls and patients during
several clearance collections obtained after sodium sulfate infusion.
The controls and three patients consistently lowered the urine pH
below 5.5. The remaining six patients failed to lower the urine pH below
5.5.
plasma renin activity but plasma aldosterone and the plasma
aldosterone/plasma potassium ratio were not diminished. The
remaining four patients (2, 7, 8, and 9) exhibited low levels of
plasma renin activity, plasma aldosterone, and plasma aldoster-
one/plasma potassium ratio after acute volume contraction.
Two of them (8 and 9) suffered from prolonged diabetes, had
hyperkalemic hyperchioremic metabolic acidosis, and were
able to lower the urine pH normally in the presence of sponta-
neous acidosis. Thus, they fulfilled the criteria for the diagnosis
of the syndrome of isolated hyporeninemic hypoaldosteronism
[36—401. The inability to lower the urine pH normally despite
systemic acidosis in the remaining two patients (2 and 7), who
also exhibited low levels of aldosterone, suggested that factors
in addition to selective aldosterone deficiency were responsible
for the generation of DRTA (see below). The low plasma
aldosterone of patient 2 could have been the result of chronic
potassium depletion due to diarrhea.
Response to sodium sulfate infusion. The capacity for distal
acidification in patients with DRTA, was investigated by sodi-
um sulfate administration (Table 3 and Fig. 1). The three normal
control subjects lowered the urine pH maximally (4.74 ± 0.24).
This decrease in urine pH was accompanied by an increase in
absolute ammonium excretion, titratable acidity (TA) excre-
tion, and net acid excretion. In contrast, six patients failed to
lower the urine pH below 5.5 (6.04 ± 0.16). In these six
patients, sodium sulfate infusion also failed to produce a
significant increase in ammonium excretion, TA excretion, or
net acid excretion.
A response to sodium sulfate similar to that of controls was
observed only in patient 6 who responded with a sharp fall in his
urine pH from 6.26 to 5.02; ammonium excretion, TA excre-
tion, and net acid excretion increased markedly. Because his
normal response to sodium sulfate contrasted with the abnor-
mal response of the remaining six patients who were unable to
lower the urine pH during spontaneous acidosis, this patient
was further challenged with ammonium chloride administra-
tion. This maneuver resulted in a fall in blood pH from 7.33 to
7.26; his urine pH, however, fell to only 5.75.
The two patients (8 and 9) who were able to lower the urine
pH normally with spontaneous acidosis also lowered the urine
pH with sodium sulfate. The latter maneuver, however, failed
to produce an increase in ammonium excretion, TA excretion,
or net acid excretion.
It is noteworthy that most of the remaining six patients had a
high rate of ammonium excretion corrected for GFR in spite of
their high urine pH. Prior to sodium sulfate infusion, the mean
Minimal urine pH during sodium sulfate infusion
1tients
ntroIs
I
.S #1
.
.I II •'
#7 #3
—-.——
— _#___ —
o •S o•• 8
. .o • •#8 #11
#6
#9#10 0
#12
Distal renal tubular acidosis 393
Table 4. Urine acidification measured by the urine-blood (U-B) Pco2 during phosphate infusion
Patient
GFR mI/mm
P4
mmoles/liter
PHCO3
mEqlliter
-_______
P0,
mm Hg
-——
U0,
mm Hg Urine pH
U,04
mmoles/liter
U-B Pco2
mm Hg
no. B P B P B P B P B P B P B P B P
1 68 63 1.1 2.8 17 14 29 27 19 19 6.84 6.57 5 20 —10 —8
2 38 39 1.0 1.9 25 24 48 43 46 49 6.72 6.40 6 28 —2 6
3 34 47 1.9 2.1 16 22 32 37 27 48 5.97 7.02 8 33 —5 11
4 31 29 1.2 5.3 19 25 34 32 29 44 6.35 6.74 4 27 —5 12
5 9 17 1.8 2.5 18 22 38 41 21 44 5,71 7.20 15 15 —17 3
7 15 15 1.6 3.9 21 21 45 42 45 35 6.24 6.61 10 16 0 —7
Mean 32.5 35 1.3 3.lb 19 21 38 37 31 40 6.3 6.7 8.0 23.2' —6.5 2.8
±SEM ±8.2 ±8 ±0.1 ±0.5 ±1 ±1.6 ±3 ±3 ±5 ±5 ±0.2 ±0.1 ±1.6 ±3.0 ±2.5 ±3.5
6 55 53 1.3 3.2 16 16 29 29 43 64 7.29 7.10 9 55 14 35
8 52 48 1.4 2.5 20 30 44 40
Controls
40 80 4.9 7.07 15 15 —4 40
10 110 114 1.2 3.2 27 29 39 40 56 70 5.72 6.87 37 86 17 30
11 146 161 1.0 3.2 26 27 42 42 30 81 6.30 6.64 6 26 —12 39
12 44 39 1.0 3.1 23 24 45 50 57 75 5.19 6.40 10 30 12 25
Mean 100 104 1.1 3.U' 25.4 26.8 42 44 47.6 75.5 5.73 6.61 18 47b 5.6 31b
±SEM ±29 ±35 ±0.06 ±0.0 ±1.2 ±1.6 ±2 ±3 ±8.6 ±3.1 ±.31 ±.15 ±9 ±19 ±8.9 ±4
B denotes baseline; P, neutral phosphate infusion.
b P < 0.02 as compared to prephosphate infusion values.
blood pH of the patients with DRTA, however, was significant-
ly lower than that of the controls (7.33 ± 0.02 vs. 7.39 ± 0.02,
P < 0.01). Most likely, the relatively high acid excretion of
patients with DRTA as compared with controls was due to the
presence of metabolic acidosis in the patients but not in the
controls. Table 3 includes renal potassium excretion in re-
sponse to sodium sulfate infusion. Notice that this agent
resulted in an increase in fractional potassium excretion in
patients and controls. This, was associated with a comparable
increase in fractional sodium excretion in all cases.
Response to neutral phosphate infusion. The results obtained
with the neutral phosphate infusion are summarized in Table 4
and Fig. 2. The urinary pH during the neutral phosphate
infusion ranged from 6.40 to 7.20 (patients, 6.83 ± 0.08; con-
trols, 6.61 ± 0.15). Before phosphate infusion neither patients
nor controls displayed a significant elevation of U-B Pco2
gradient. Following phosphate infusion, urinary phosphate con-
centration increased in all cases to above 15 mrt. As a result of
phosphate infusion, the U-B Pco2 gradient increased above 25
mm Hg in all controls (from a mean of 5.6 ± 8.9 to 31.3 ± 4.1
mm Hg, P < 0.02). Two of the three patients (6 and 8) who had
lowered the urine pH normally with sodium sulfate also were
able to achieve a similarly large U-B Pco2 gradient (Table 3).
The third patient (9) was not tested with neutral phosphate. The
remaining six patients failed to achieve a substantial U-B Pco2
gradient (2.8 ± 3.5 mm Hg) during phosphate infusion in spite
of similar conditions of urinary pH and phosphate buffer
concentration. These six patients also had failed to lower the
urine pH normally with sodium sulfate.
Discussion
The diagnosis of DRTA is generally made by the inability to
lower the urine pH to normal minimum levels (that is, below
5.5) in the presence of systemic metabolic acidosis. The failure
to lower the urine pH, however, does not indicate the mecha-
nism responsible for impaired distal acidification which leads to
hyperchioremic metabolic acidosis. As suggested by Steinmetz,
"there is not an a priori reason why there should be a single
0
—5
—10
—15
10 20 30 40 50 60
Urine phosphate, m
Fig. 2. Relationship between urine-blood Pco2 and urine phosphate
concentration at a urine pH close to 6.8 (ranging from 6.4 to 7.2). With
urine phosphate concentrations above 20 m, the controls and two
patients (responders) achieved a urine-blood Pco2 above 25 mm Hg.
The remaining six patients (nonresponders) exhibited a urine-blood
Pco2 consistently lower than 15 mm Hg at comparable levels of urine
phosphate concentration.
mechanism for the different disease entities associated with
DRTA or for that matter, for an individual case of DRTA" [3].
This contention is gaining support from experimental models of
distal acidification defects, which indicate that more than one
mechanism is capable of impairing distal acidification [14—20].
The urine pH reaches its lowest value in the distal nephron,
presumably in the collecting duct [41]. Active proton secretion
appears to be dependent on the integrity of a proton specific
pump and is influenced by the electrical and chemical gradients
against which the pump operates [3, 4]. The electrical gradient
is influenced by the rate of sodium transport and the amount
and nature of anions present in the lumen of the distal nephron.
0
IA • •.
r. • .
o 0
o00d .
0 0
Urine pH (6.4 to 7.2)
U
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£
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(nonresporiders)
Patients A A
(responders)
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Table 5. Pathophysiologic features of secretory, voltage-dependent DRTA and selective aldosterone deficiency
Type Mechanism
1. Secretory Intrinsic H pump failure
DRTA
II. Reversible
voltage-
dependent
DRTAa
III. Aldosterone
deficiency
Decreased H
conductance;
decreased
Na reabsorption;
decreased ammonia
production
Urine pH U-B Pco2
HCO3 P04
Acidemia Na2SO4 loading loading PK
>5.5 >5.5 <10 <10 Normal
or
>5.5 <5.5 <I0 >25 f
The chemical hydrogen ion gradient is obviously dependent on
the luminal pH and probably on the intracellular pH as well.
The rate of hydrogen ion secretion is modulated by aldosterone,
a hormone that increases the proton conductance of the distal
nephron and enhances luminal electronegativity by increasing
sodium transport [42]. The acidification process also includes a
passive component that relates to the backleak of acid from
lumen to blood and the leak of bicarbonate from blood to
lumen; the significance of the passive component is still uncer-
tain.
Theoretically, impaired distal acidification could result from
a defect in any of the above mentioned components of acidifica-
tion. The view that has prevailed for about 30 years is that
DRTA results from the inability of the distal nephron to
maintain a steep hydrogen ion gradient between the extracellu-
lar fluid and the tubular urine (gradient DRTA) [1—4, 6, 9—12].
This view was challenged by the findings that patients with
DRTA failed to increase the U-B Pco2 (an index of distal
hydrogen ion secretion) when a favorable hydrogen ion gradient
was imposed by maximal alkalinization of the urine [13]. Based
on these findings, Halperin et al proposed that the mechanism
responsible for DRTA was that of a secretory defect for
hydrogen ions [13]. An objection to this proposal is that a low
U-B Pco2 during bicarbonate loading could also be the result of
backleak of secreted acid (hydrogen ions or carbonic acid)
because the rise in the U-B Pco2 is dependent on the present of
sufficient carbonic acid concentrations in the collecting duct
[43].
Failure to secrete hydrogen ions would likely be manifested
by the inability to acidify the urine normally with any of the
various maneuvers known to stimulate the distal acidification
apparatus. In this study, the mechanism(s) responsible for
DRTA was investigated by the systematic administration of
sodium sulfate and neutral phosphate. Sodium sulfate results in
a prompt fall in urine pH in normal subjects and patients with
chronic renal failure retaining salt avidly [44, 45]. It favors the
electrical gradient for hydrogen ion secretion by increasing
distal delivery of sodium and a poorly reabsorbable anion [44].
Neutral phosphate not only stimulates acidification by increas-
ing the electrical gradient, but also by minimizing the pH
gradient against which hydrogen ions are secreted by virtue of
its buffer properties.'
Our findings that six of our seven patients with DRTA failed
to lower the urine pH with sodium sulfate (Fig. 1) and also failed
to achieve a normal U-B Pco2 with neutral phosphate (Fig. 2)
provide the strongest evidence available that DRTA in these
patients was due to an isolated secretory defect in the distal
nephron (secretory DRTA). It must be emphasized, however,
that definitive support for this mechanism awaits the demon-
stration of a normal response to these agents in patients with
DRTA due to a nonsecretory mechanism (that is, increased
backleak of acid2).
One patient (patient 6) with DRTA had a distinctive pattern of
urinary acidification. He failed to lower the urine pH normally
during systemic acidosis, but he responded normally to both
sodium sulfate and neutral phosphate administration. This
pattern could be the result of a partial secretory defect for
hydrogen ion ( weak proton pump"), which responds to maxi-
mal stimulation of the distal acidification apparatus. This pa-
tient, however, was also distinctive in that he was hyperkalemic
despite a normal plasma aldosterone concentration. An in-
crease in luminal electronegativity facilitates both hydrogen ion
and potassium secretion; this may be achieved by sodium
sulfate administration. That this patient was able to lower the
urine pH and increase potassium excretion with sodium sulfate
infusion is consistent with a reversible form of voltage-depen-
dant DRTA (see below). In contradistinction, all the remaining
six patients with DRTA increased potassium excretion but they
'Providing that the urine pH is closed to the pK of the phosphate
buffer system in the urine (that is, 6.8), phosphate binds the secreted
hydrogen ions and later releases hydrogen ions which react with
bicarbonate ions; thus, a normal secretory capacity for hydrogen ions is
reflected by an increase in urine Pco2 [18].
2Acid backleak is the likely mechanism of DRTA induced by ampho-
tericin B, a drug well known to increase membrane permeability. In this
case, sodium sulfate infusion could result in a normal fall in urine pH by
increasing lumen electronegativity and thereby restricting back diffu-
sion of secreted acid. Likewise, neutral phosphate infusion could result
in a normal acidification response by buffering secreted hydrogen ions,
which would be less diffusible.
Impairment of distal Na
transport or enhanced
Cl permeability
Baseline
Normal
or
FEK
Stimulated Example
Classical DRTA
1' SC disease
<5.5 <5.5 >25 >25 . Isolated hyporeninemic
hypoaldosteronism
An irreversible type of voltage-dependent defect should be associated with all the features of a secretory defect plus impaired potassium
excretion during stimulation [481. A pattern similar to that of a reversible voltage-dependent defect could be expected in DRTA secondary to acid
backleak (that is, amphotericin B toxicity). In this case, however, potassium excretion would be increased with attendant hypokalemia.
b A subnormal U-B Pco2 during bicarbonate loading is predictable based on animal models of voltage-dependent DRTA [15, 16].
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failed to lower the urine pH in response to sodium sulfate
infusion (Table 3). This pattern suggests that they were able to
generate a transtubular electrical gradient and thereby increase
potassium excretion. The failure to lower the urine pH in this
setting further suggests thay they had an isolated failure of the
proton pump as the mechanism responsible for their DRTA.
That some patients with DRTA (that is, patient 6) are
hyperkalemic despite normal aldosterone suggests the presence
of a distinctive type of distal tubular dysfunction. A diffuse
distal tubular defect for both hydrogen ion and potassium
secretion is not likely since the great bulk of potassium is
derived into the lumen of the distal nephron by passive translo-
cation 1461. Therefore, it seems logical to speculate that the
hyperkalemic DRTA of our patient 6 was the consequence of
inability to generate a transtubular electrical gradient for hydro-
gen ion and potassium secretion (voltage-dependent DRTA).
The most likely cause for a voltage-dependent defect is a
primary impairment in sodium reabsorption. In support of this
contention are the recent findings of impaired maximal sodium
conservation in a patient with voltage-dependent DRTA associ-
ated with hemoglobinopathy S [471. Depending on the nature of
the defect for sodium transport, impairment for hydrogen ion
and potassium secretion may or may not be reversed by
enhanced distal sodium delivery (that is. sodium sulfate infu-
sion). A voltage-dependent type of acidification defect can be
induced experimentally with amiloride administration [16]. In
this case, sodium sulfate does not correct the defect presumably
because the presence of amiloride irreversibly blocks the cellu-
lar channels for sodium transport. A pattern of impaired hydro-
gen ion and potassium secretion similar to that caused by
amiloride is present in patients and animals with obstructive
uropathy [20, 481. A reversible form of voltage-dependent
DRTA can be induced experimentally by lithium administration
[15], This is associated with a normal response to sodium
sulfate and neutral phosphate infusions [18. 19]. The pattern of
hydrogen ion and potassium excretion in response to sodium
sulfate observed in patient 6 is consistent with a reversible type
of voltage-dependent DRTA.
It should be noted that voltage-dependent DRTA may result
from enhanced chloride reabsorption rather than decreased
sodium transport in some patients. A patient recently described
by Shambelan, Sebastian, and Rector appears to represent this
mechanism of a "chloride shunt" [49]. In this case, hyperten-
sion was present and plasma renin activity and plasma aldoster-
one were low while on a normal salt diet, presumably reflecting
volume expansion from enhanced salt retention [49]. A normal
increase in potassium excretion was demonstrated when the
patient was given sodium sulfate after salt restriction [49].
In our study, hyperkalemia was recognized in three other
patients. Two of these patients (8 and 9) had the typical features
of selective aldosterone deficiency [36—40]. This entity is con-
sidered a form of RTA (type IV RTA) by some authors [401.
Urinary acidification in this syndrome is characterized by a
maximally acidic urine during acidosis as well as a normal U-B
Pco2 during alkalinization of the urine [36—40]. Predictably, our
study shows that these patients are also able to generate a
normal U-B Pco2 gradient during neutral phosphate infusion.
Selective aldosterone deficiency was also present in the third
hyperkalemic patient (7, Table 2). This patient failed to acidify
the urine during acidosis and after sodium sulfate and neutral
phosphate administration. Clearly, he had a distal acidification
defect that could not be solely accounted by aldosterone
deficiency. Thus, it is worthy of emphasis that aldosterone
deficiency can coexist with an intrinsic distal acidification
defect [481.
TableS summarizes the features of secretory DRTA, voltage-
dependent DRTA, and selective aldosterone deficiency. This
table is based on the findings of this study and the pathogenetic
mechanisms discussed above. Although the U-B Pco2 during
bicarbonate loading was not measured in the present study, an
abnormal response to alkalinization of the urine is expected in
any patient that responds abnormally to sodium sulfate and
neutral phosphate administration.
Summary. Our study indicates that many patients with
DRTA do not acidify the urine normally with either sodium
sulfate or neutral phosphate administration. This pattern is the
strongest evidence available against the theory that DRTA
results from inability to maintain a transtubular pH gradient. It
rather suggests the presence of a "broken" hydrogen ion
secretory pump (secretory DRTA). In these patients potassium
excretion is not impaired when aldosterone deficiency is not
present. On the other hand, a normal response to either sulfate
or phosphate indicate that the hydrogen ion pump is either
intact or less severely damaged. In hyperkalemic patients, the
kaliuretic and acidification response to sodium sulfate can be
used to reveal a voltage-dependent type of distal tubular
dysfunction.
Acknowledgments
This research was supported in part by VA Central Office Grant
#7083, Chicago Heart Association Grant #A79-28, and USPHS Grant
#AM2O 170. We thank Doctors G. Lang, F. Schwartz. and 0. Jonasson
for referring their patients to us for this study.
Reprint requests to Dr. D. C. Batile, Section of Nephrology, Univer-
sit y of Illinois Hospital, 840 South Wood Street, Chicago, Illinois
60612, USA
References
I. MoRRIs RC JR: Renal tubular acidosis: Mechanisms, classification
and implications. N EngI J Med 28t:l405—1413, 1969
2. STEINMETZ PR, AL-AWQUATI Q, LAWSON WJ: Renal tubular
acidosis. Nephrology Rounds, University of Iowa Hospitals. Am J
Med Sd 271:40—54, 1976
3. STEINMETZ PR: Cellular mechanisms in urinary acidification and
renal tubular acidosis, in Physiology of Membrane Disorders,
edited by ANDREOLI TE, HOFFMAN J, FANESTIL D, New York,
Phenum Press. 1979, p 987—1017
4. STEINMETZ PR: Cellular mechanisms of urinary acidification. Phy-
siol Rev 54:890—956, 1974
5. R0DRIGUEz-S0RIAN0 J, EDELMANN CM JR: Renal tubular acido-
sis. Ann Rev Med 20:363-382, 1969
6. SEBASTIAN A, MCSHERRY E, MORRIS RC Ja: Metabolic acidosis
with special reference to the renal acidosis, in The Kidney, edited
by BRENNER BM, RECTOR FC JR. Philadelphia, Saunders, 1976, vol
1, pp 615—660
7. GILL JR JR, BELL NH, BARTTER FC: Impaired conservation of
sodium and potassium in renal acidosis and its correction by buffer
anions. Clin Sci 33:577—592, 1967
8. SEBASTIAN A, MCSI-IERRY E, MORRIS RC JR: Renal potassium
wasting in renal tubular acidosis: Its occurrence in types 1 and 2
despite sustained correction of systemic acidosis. J Clin Invest
50:667—678, 1971
9. SELDIN DW, WILSON JD: Renal tubular acidosis, in The Metabolic
Basis of inherited Diseases (3rd ed), edited by STANBURY JB,
WYNGARDEN J, FREDERICKSON DS, New York, McGraw Hill Book
Co, 1971, pp 1548—1566
396 Battle et a!
10. SIMPSON DP: Control of hydrogen ion homeostasis and renal
acidosis. Medicine 50:503-541, 1971
II. REYNOLDS TB: Observations on the pathogenesis of renal tubular
acidosis. Am J Med 25:503—515, 1958
12. WRONG 0, DAVIESHEF:The excretion of acid in renal disease. QJ
Med 28:259—313, 1959
13. HALPERIN ML, GOLDSTEIN MB, HAIG A, JOHNSON MD,
STINEBAUGH BJ: Studies on the pathogenesis of type 1 (distal) renal
tubular acidosis as revealed by the urinary pCO2 tensions. J C/in
Invest 53:669—677, 1974
14. STEINMETZ PR, LAWSON WJ: Defect in urinary acidification in-
duced in vitro by amphotericin B. J C/in Invest 49:596—1970
15. ARRUDA JAL, DYTKO G, MOLA R, KURTZMAN NA: Characteriza-
tiOn of the acidification defect induced by Li: Studies in the turtle
bladder. Kidney In! 17:196—204, 1980
16. ARRUDA JAL, SUBBARAYUDU K, DYTKO G, MOLA R, KURTZMAN
NA: Voltage dependent distal acidification defect induced by
amiloride. J Lab C/in Med 95:407—412, 1980
17. ARRUDA JAL, KURTZMAN NA: Mechanisms and classification of
deranged distal urinary acidification. Am J Physio/ 239:F515—223,
1980
18. ARRUDA JAL, NASCIMENTO L, KUMAR S, SODHI B, KURTZMAN
NA: Factors influencing the formation of urinary carbon dioxide
tension. Kidney In! 11:307—317, 1977
19. NASCIMENTO L, RADEMACHER D, HAMBURGER R, ARRUDA JAL,
KURTZMAN NA: On the mechanism of lithium-induced renal tubu-
lar acidosis. J Lab C/in Med 89:455—462, 1977
20. THIRAKOMEN K, KOZLOV N, ARRUDA JAL, KURTZMAN NA:
Renal hydrogen ion secretion following the release of unilateral
ureteral obstruction. Am J Physio/ 231:1233—1239, 1976
21. ARRUDA JAL, KURTZMAN NA: Metabolic acidosis and alkalosis.
C/in Nephro/ 7:201—215, 1977
22. BATLLEDC, MOZES M, MANALIGOD J, ARRUDA JAL, KURTZMAN
NA: The pathogenesis of hyperchloremic metabolic acidosis asso-
ciated with kidney transplantation. Am J Med, 70:786—796, 198l
23. BUCKALEW VM JR, MCCURDY DK, LUDWIG GD, CHAYKIN LB,
ELKINTON JR: Incomplete renal tubular acidosis. Physiologic stud-
ies in three patients with a defect in lowering urine pH. Am J Med
45:32—43, 1968
24. FRICK PG, RuBINI ME, MERONEY WH: Recurrent nephrolithiasis
associated with an unusual tubular defect and hyperchloremic
acidosis. Am J Med 25:590—599, 1958
25. GYORY AZ, EDWARDS KDG: Effect of mersalyl, ethacrynic acid
and sodium sulfate infusion on urinary acidification in hereditary
renal tubular acidosis. Med J Aust 2:940—945, 1971
26. MoRRIS RC, PIEL CF, AUDIOUN E: Renal tubular acidosis. Effects
of sodium phosphate and sulfate on renal acidification in two
patients with renal tubular acidosis. Pediatrics 36:899—904, 1965
27. ROYER P, LESTRADET J, NORDMANN R, MATHIEU J, RODRIGUEZ-
SORIANO J: Etudes sur quatre cas d'acidose tubulaire chronique
idiophathique avec hypocitraturie. Sem Hop Paris 38:808—829,
1962
28. SCHREINER GE, SMITH LH, KYLE LH: Renal hyperchloremic
acidosis; familial occurrence of nephrocalcinosis with hyperchiore-
mia and low serum bicarbonate. Am J Med 15:122—129, 1953
29. SELDIN DW, RECTOR FC JR, PORT WOOD R, CARTER N: Pathogene-
sis of hyperchloremic acidosis in renal tubular acidosis. Proc 1st Int
CongrNephrol, GenevelEvian 1960, 1961, p. 725
30. SMITH LH JR, SCHREINER GE: Studies on renal hyperchloremic
acidosis. J Lab C/in Med 43:347—358, 1954
31. TANNEN RL, FALLS WF, BRACKETT NC: Incomplete renal tubular
acidosis: Some clinical and physiological features. Nephron
15:111—123, 1975
32. MURRAY T, GOLDBERG M: Chronic interstitial nephritis: Etiologic
factors. Ann Intern Med 82:453—459, 1975
33. STEINMETZ PR, BANK N: Effects of acute increases in the excre-
tion of solute and water on renal acid excretion in man. J C/in
Invest 42:1142—1 159, 1963
34. KURTZMAN NA: Regulation of renal bicarbonate reabsorption by
extracellular volume, J C/in lnvest 49:586—595, 1970
35. CUNNARRO JA, WEINER MW: A comparison of methods for
measuring urinary ammonium. Kidney Int 5:303—305, 1974
36. BATTLE D: Hyperkalemic hyperchloremic metabolic acidosis asso-
ciated with selective aldosterone deficiency and distal renal tubular
acidosis. Sem Nephro/ 1, in press, 1981
37. HULTER HN, ILNICKI LP, HARBOTTLE JA, SEBASTIAN A: Impaired
renal H secretion and NH3 production in mineralocorticoid-
deficient glucocorticoid replete dogs. Am J Physio/ 232(2):Fl36—
F146, 1977
38. DITELLA P, S0DHI B, MCCREARY J, ARRUDA JAL, KURTZMAN
NA: The mechanism of the metabolic acidosis of selective mm-
eralocorticoid deficiency. Kidney mt 14:466—477, 1978
39. PEREZ GO, OSTER JR, VAAMONDE CA: Renal acidosis and renal
potassium handling in selective hypoaldosteronism. Am J Med
57:809—816, 1974
40. SEBASTIAN A, SCHAMBELAN M, LINDENFELD S. MORRIS RC JR:
Amelioration of metabolic acidosis with fludrocortisone therapy in
hyporeninemic hypoaldosteronism. N Engi J Med 297:576—583,
1977
41. RECTOR RC Jg: Acidification of the urine, in Handbook of Physio/-
ogy, edited by ORLOFF J, BERLINER RW, Baltimore, Maryland,
Williams and Wilkins Company, 1973, pp 431—454
42. AL-AWQATI Q, NORBY LH, MUELLER A, STEINMETZ PR: Charac-
teristics of stimulation of H transport by aldosterone in turtle
urinary bladder. J C/in Invest 58:35 1—358, 1976
43. SEBASTIAN A, MCSHERRY E, MORRIS RC JR: On the mechanism of
inappropriately low urinary carbon dioxide tension (U-B pCO2) in
classic (type I) renal tubular acidosis (RTA) (abst). C/in Res
22:544A, 1974
44. SCHWARTZ WB, JENSON RL, RELMAN AS: Acidification of the
urine and increased ammonia excretion without change in acid-base
equilibrium: Sodium reabsorption as a stimulus to the acidifying
process. J C/in Invest 34:673—680, 1955
45. SELDIN DW, COLMAN AJ, CARTER N, RECTOR FC JR: The effect of
Na2SO4 on urinary acidification in chronic renal disease. J Lab C/in
Med 69:893—903, 1967
46. GARCIA-FILHO E, MALNIC G, GIEBISCH G: Effects of changes in
electrical potential difference on tubular potassium transport. Am J
Physio/ 238:F235—F246, 1980
47. BATLLE DC, LTSARAYOUNGYUEN K, ARRUDA JAL, KURTZMAN
NA: Hyperkalemic hyperchioremic metabolic acidosis in patients
with sickle cell hemoglobin (abst). Proc Am Soc Nephro/ 1980, 12A
48. BATLLE DC, ARRUDA JAL, KURTZMAN NA: Hyperkalemic distal
renal tubular acidosis associated with obstructive uropathy. N Eng/
JMed, 304:373—380, 1981
49. SCHAMBELAN M, SEBASTIAN A, RECTOR FC JR: Mineralocorticoid
resistant renal potassium secretory defect: proposed distal tubule
chloride shunt (abst). C/in Res 26:545A, 1978
